We are live on ! Find out more
BBH icon

VanEck Biotech ETF
BBH

108 hedge funds and large institutions have $132M invested in VanEck Biotech ETF in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 38 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.67% less ownership

Funds ownership: 30.64% → 29.97% (-0.67%)

6% less funds holding

Funds holding: 115 → 108 (-7)

11% less capital invested

Capital invested by funds: $147M → $132M (-$15.8M)

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

63% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 38

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $233K

Holders
108
Holders Change
-7
Holders Change %
-6.09%
% of All Funds
1.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
14
Reduced
38
Closed
18
Calls
–
Puts
$233K
Net Calls
-$233K
Net Calls Change
-$1.01M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$11.5M
2
CAN
Cetera Advisor Networks
California
+$1.08M
3
Bank of America
Bank of America
North Carolina
+$992K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$923K
5
TRCT
Tower Research Capital (TRC)
New York
+$693K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.69M
2
Goldman Sachs
Goldman Sachs
New York
-$2.68M
3
LFASL
Lugano Financial Advisors SA (LFA)
Switzerland
-$1.35M
4
NFG
Norris Financial Group
South Carolina
-$1.24M
5
WANY
Wealthspire Advisors (New York)
New York
-$1.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
EIP
76
Ellis Investment Partners
Pennsylvania
$51K – – –
SWM
77
SeaCrest Wealth Management
New York
$48K +$49.2K +330 New
FDCDDQ
78
Federation des caisses Desjardins du Quebec
Quebec, Canada
$43.7K – – –
AF
79
Arrow Financial
New York
$36K – – –
TC
80
Truvestments Capital
Florida
$36K +$37.2K +250 New
Qube Research & Technologies (QRT)
81
Qube Research & Technologies (QRT)
United Kingdom
$35K +$35.9K +241 New
LFASL
82
Lugano Financial Advisors SA (LFA)
Switzerland
$29K -$1.35M -9,057 -98%
First Manhattan
83
First Manhattan
New York
$29K – – –
AIM
84
Anchor Investment Management
South Carolina
$24.1K – – –
US Bancorp
85
US Bancorp
Minnesota
$22K – – –
EDRH
86
Edmond de Rothschild Holding
Switzerland
$19K – – –
AF
87
Allworth Financial
California
$17K -$149 -1 -0.8%
WT
88
Whittier Trust
California
$15K – – –
FCMT
89
Founders Capital Management (Texas)
Texas
$15K +$14.9K +100 New
FP
90
Financial Perspectives
Minnesota
$12.8K – – –
CAPTRUST Financial Advisors
91
CAPTRUST Financial Advisors
North Carolina
$12K – – –
HWM
92
HighMark Wealth Management
Minnesota
$12K – – –
National Bank of Canada
93
National Bank of Canada
Quebec, Canada
$11K – – –
HI
94
Harbour Investments
Wisconsin
$9K +$9.68K +65 New
CPFP
95
Clear Perspectives Financial Planning
Ohio
$8K -$51.4K -345 -86%
AA
96
Ancora Advisors
Ohio
$7K – – –
Citigroup
97
Citigroup
New York
$7K – – –
GFPC
98
Global Financial Private Client
Florida
$6.56K – – –
Fidelity Investments
99
Fidelity Investments
Massachusetts
$5K -$10.9K -73 -67%
SIAP
100
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$5K +$5.06K +34 New
2 3
4
5 6

BBH Hedge Fund Activity: Q2 2022 in Review

108 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2022, worth a combined $132M — down 11% from $147M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of BBH and 14 opened new positions — a net loss of 4 holders — while 38 trimmed existing stakes and 14 added.

The largest buyer was JP Morgan Chase, opening a new position worth an estimated $11.5M. The largest seller was Susquehanna International Group, cutting an estimated $2.69M.

  • 108 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2022, down from 115 in Q1 2022.
  • Funds reported $132M of VanEck Biotech ETF stock for Q2 2022, down 11% quarter-over-quarter.
  • 14 funds opened new VanEck Biotech ETF positions in Q2 2022 and 18 closed out, a net change of -4 holders.
  • The largest VanEck Biotech ETF buyer in Q2 2022 was JP Morgan Chase, an estimated $11.5M added.
  • The largest VanEck Biotech ETF seller in Q2 2022 was Susquehanna International Group, an estimated $2.69M sold.

Based on aggregated 13F filings for Q2 2022.